Subscribe to NRx Newsletter

Sars-CoV-2

CEO Update: Report on BriLife’s® Serologic Response to Omicron

NRx is excited about the most recent report published by the Israeli Institute of Biological Research on the BriLife® vaccine. The scientific report shows serologic response against the Omicron variant in patients vaccinated during the phase 2 clinical trial of BriLife® against Sars-CoV-2 coronavirus. Ten of 13 vaccinated subjects demonstrated detectable neutralizing antibody against Omicron. […]

CEO Update: Letter to Shareholders

To Our Shareholders,             We have received many inquiries from shareholders following the recent encouraging news regarding Merck’s Molnupiravir results in early COVID-19.  We have also received various questions about the status of our application to the US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for ZYESAMI. Needless to say, we are […]

CEO Update: July 21, 2021 Panel Discussion hosted by the Disease Prevention & Control Summit

On Wednesday, July 21, 2021, Prof Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals, participated in a panel discussion hosted by the Disease Prevention & Control Summit. The specific panel discussion focused on small molecules and repurposed medicines for COVID-19 treatment. Jonathan received several questions from those watching the panel discussion. Below, are […]